公开(公告)号：US20230099018A1

公开(公告)日：2023-03-30

申请号：US17891869

申请日：2022-08-19

申请人： University of Massachusetts

发明人： Celia A. Schiffer ,  Akbar Ali ,  Ashley N. Matthew

IPC分类号： C07D241/20 ,  C07K5/083 ,  C07K5/103 ,  C07K5/107 ,  A61P31/14 ,  A61K31/498

摘要： The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof.

公开(公告)号：US20220227806A1

公开(公告)日：2022-07-21

申请号：US17607886

申请日：2020-06-05

申请人： University of Massachusetts

发明人： Celia A. Schiffer ,  Akbar Ali ,  Jacqueto Zephyr ,  Ashley N. Matthew ,  Nageswara R. Desaboini

IPC分类号： C07K5/083 ,  C07K5/107

摘要： The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof.

公开(公告)号：US20200087265A1

公开(公告)日：2020-03-19

申请号：US16614843

申请日：2018-06-19

申请人： University of Massachusetts

发明人： Celia A. Schiffer ,  Akbar Ali ,  Ashley N. Matthew

IPC分类号： C07D241/20 ,  C07K5/083 ,  C07K5/103 ,  C07K5/107

摘要： The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof.